News
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
* Researchers at the Danish Headache Center are testing semaglutide along with a very low calorie diet as a treatment for new ...
Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its ...
Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...
GoodRx reports on identifying real Wegovy pens, which come in five colors and lack dose selectors. Counterfeits pose health ...
Novo Nordisk’s weight loss drug, Wegovy, is experiencing a surge in new prescriptions following a US ban on its copycat ...
Explore more
The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
“Beyond weight loss, Wegovy has shown cardiovascular benefits such as reducing the risk of major adverse cardiovascular events in obese or overweight patients with heart disease,” says Dr. Emch.
Novo Nordisk A/S slashed its financial forecast in a surprise update that cited lagging sales of its weight-loss drug Wegovy, as the company loses ground to Eli Lilly & Co. in the obesity market. The ...
New trial results show the weight-loss medication Wegovy can also cut heart attack and stroke risks, according to the drug's maker. The maker of Wegovy is claiming the weight loss drug can also ...
Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the name-brand medicine. The company says it trying to stop them.
Danish pharmaceutical giant Novo Nordisk on Tuesday cut its full-year sales and profit guidance, citing weaker growth expectations for its Wegovy obesity drug in the key U.S. market. Shares were down ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results